A newly approved targeted therapy could offer hope for certain advanced breast cancer patients.
- Inluryo is a newly approved oral treatment for ER positive HER2 negative advanced breast cancer
- The drug works by degrading estrogen receptors that drive tumour growth
- Targeted hormone therapies are expanding treatment options for patients with resistant disease
Breast cancer remains one of the most commonly diagnosed cancers worldwide, with over 2.3 million new cases and roughly 670,000 to 685,000 deaths annually (1). Advances in targeted therapies continue to improve treatment outcomes for many patients. Recently, the MHRA, the United Kingdom medicines regulator, approved a new drug called Inluryo for certain breast cancer patients. This medication contains the active ingredient imlunestrant tosylate and represents a new form of hormone-targeted therapy (2). The approval offers another option for individuals with specific tumour characteristics.
Inluryo has been approved for adults with advanced breast cancer that is estrogen receptor positive and HER2 negative. This category represents one of the most common types of breast cancer diagnosed globally. Many patients with this cancer type respond to hormone therapies that block estrogen activity. However, resistance to treatment may develop over time. The introduction of imlunestrant therapy aims to address this treatment challenge (3).
What is ER Positive HER2 Negative Breast Cancer?
Breast cancers are often classified based on hormone receptor and protein expression patterns. Estrogen receptor-positive cancers rely on estrogen to support tumour growth. HER2-negative cancers do not overexpress the HER2 protein associated with aggressive tumour behaviour. Together, this category is referred to as ER-positive HER2-negative breast cancer. This subtype accounts for a large proportion of breast cancer diagnoses.
Hormone therapies are commonly used to slow tumour growth in these patients. Treatments such as aromatase inhibitors and selective estrogen receptor modulators block estrogen signaling pathways. While these therapies are effective initially, some tumours gradually develop resistance. Researchers have therefore explored newer approaches to disrupt estrogen signaling more effectively. Targeted medicines like imlunestrant represent one such strategy.
How Inluryo Works As A Hormone Targeted Therapy for Breast Cancer
Inluryo belongs to a class of medicines known as selective estrogen receptor degraders. These drugs work by binding directly to estrogen receptors within cancer cells. Once attached, the drug causes the receptor to break down and lose function. This process reduces the tumour’s ability to use estrogen for growth. The drug therefore interferes with a key driver of hormone-dependent cancer growth.
Unlike some earlier therapies, imlunestrant is designed to be taken orally as a tablet. This may provide greater convenience compared with injectable hormone therapies. By degrading estrogen receptors, the drug aims to overcome resistance that develops with older treatments. Clinical trials have evaluated its ability to delay cancer progression. These findings supported regulatory approval for specific patient groups.
Clinical Trial Evidence Supporting Inluryo For Advanced Breast Cancer
The approval of Inluryo was supported by results from large international clinical studies. One key trial examined patients with advanced ER-positive HER2-negative breast cancer whose disease had progressed after prior therapy. Researchers compared outcomes between those receiving imlunestrant and those receiving standard treatments. Results demonstrated improved progression-free survival in certain patient populations.
Scientific publications in journals such as The New England Journal of Medicine have highlighted the growing role of receptor-degrading therapies (4). These treatments aim to target cancer biology more precisely than traditional hormone-blocking drugs. Clinical trial data also examined safety and tolerability profiles. Most side effects were manageable with appropriate medical supervision. Continued research will further clarify long-term benefits.
Who May Benefit From Treatment with Inluryo
Inluryo is intended for adults with advanced or metastatic breast cancer meeting specific molecular criteria. Patients must have ER-positive and HER2-negative tumours. The treatment is generally considered after prior hormone therapies have stopped working effectively. Doctors will evaluate individual tumour characteristics before recommending this therapy.
Not every patient with breast cancer will be eligible for this medication. Diagnostic testing helps identify individuals who are most likely to benefit. Oncology specialists carefully review treatment history, tumour biology, and overall health status. Personalized medicine continues to shape modern cancer care. This ensures therapies are matched with patients most likely to respond.
The Future Of Hormone Targeted Cancer Therapies
The approval of Inluryo reflects broader progress in precision oncology research. Scientists continue to explore treatments that target specific molecular pathways in cancer cells. Advances in genomic testing allow clinicians to select therapies more accurately. Such approaches aim to improve survival while reducing unnecessary side effects. New options like targeted hormone therapies expand the treatment landscape.
Ongoing studies are evaluating combinations of imlunestrant with other cancer medicines. Combining targeted therapies may enhance treatment effectiveness in resistant tumours. Researchers are also exploring whether these drugs can benefit patients earlier in the disease course. Continued clinical trials will help refine treatment strategies further. Progress in breast cancer research offers renewed hope for patients worldwide.
Frequently Asked Questions
What is Inluryo used for?
Inluryo is used to treat adults with ER-positive HER2-negative advanced or metastatic breast cancer.
How does imlunestrant work?
Imlunestrant works by degrading estrogen receptors that help certain breast cancers grow.
Is Inluryo taken as a pill?
Yes, Inluryo is taken orally as a tablet under medical supervision.
Who can receive this treatment?
Patients with ER-positive HER2-negative breast cancer who have progressed after prior therapies may be eligible.
Does this drug cure breast cancer?
This treatment helps slow disease progression but is not considered a cure.
References:
- Current and future burden of breast cancer: Global statistics for 2020 and 2040
(Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2. PMID: 36084384; PMCID: PMC9465273.) - MHRA approves imlunestrant tosylate (Inluriyo) – a new treatment for breast cancer
(https://www.gov.uk/government/news/mhra-approves-imlunestrant-tosylate-inluryo-a-new-treatment-for-breast-cancer) - Inluriyo (imlunestrant) for ESR1-mutant breast cancer: modest gains, unmet concerns
(Sadia Z, Azhar Z, Ekouo J. Inluriyo (imlunestrant) for ESR1-mutant breast cancer: modest gains, unmet concerns. Ann Med Surg (Lond). 2025 Nov 24;88(1):1015-1016. doi: 10.1097/MS9.0000000000004357. PMID: 41497127; PMCID: PMC12768226.) - Degradation of the Estrogen Receptor in Breast Cancer
(DOI: 10.1056/NEJMe2507193)
Source-Medindia